Key facts
- ASTRA Therapeutics’s last known valuation is $28.0M (Jul 2025).
- It has raised $9.7M; the latest was Later Stage VC ($9.7M) in Jul 2025.
- Notable investors include Venture Kick, Kickfund, Digitalis Ventures, Borealis Ventures, Gebert Rüf Foundation — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for ASTRA Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for ASTRA Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ASTRA Therapeutics
Developer of an anti-parasite technology intended to provide therapies for parasitic diseases such as malaria. The company offers a technology to fight against a broad range of parasites with precision-engineered drugs, enabling individuals to get cures for parasitic diseases like malaria, cryptosporidiosis, and toxoplasmosis.
- Sector
- Healthcare
- HQ
- Villigen, Switzerland
- Founded
- 2019
- Employees
- 4
- Website
- astratherapeutics.com/
- Ownership
- Privately Held (backing)
ASTRA Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ASTRA Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ASTRA Therapeutics in its N-PORT filings yet. We sweep new filings monthly.